 BOSTON SHANGHAI LAUSANNE, Switzerland--BUSINESS WIRE--Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics SA NYSE: ADCT, today announced the first patient has been dosed with ZYNLONTA in a pivotal Phase 2 clinical trial in patients with relapsed or refractory rr diffuse large B-cell lymphoma DLBCL in China. In April 2021, ZYNLONTA was granted accelerated approval by the U.S. Food and Drug Administration FDA as the first and only CD19 